Zelin Li
Shijiazhuang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Corrigendum to "A metabonomics-based renoprotective mechanism analysis of empagliflozin in obese mice" [Biochem. Biophys. Res. Commun. 621 (2022) 122-129].
Journal: Biochemical and biophysical research communications
Published: September 04, 2025
The Association Between Neutrophil/High-Density Lipoprotein Cholesterol Ratio and Non-Alcoholic Fatty Liver Disease in a Healthy Population.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: February 16, 2024
Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: June 09, 2023
The Relationship Between Non-HDL-C /HDL-C Ratio (NHHR) and Vitamin D in Type 2 Diabetes Mellitus.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: March 31, 2023
The Ratio of Fibrinogen to Albumin is Related to the Occurrence of Retinopathy in Type 2 Diabetic Patients.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: February 06, 2023
Association Between Vitamin D Levels and the Atherogenic Index of Plasma Among Chinese with Type 2 Diabetes Mellitus.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: December 06, 2022
Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model.
Journal: Frontiers in endocrinology
Published: September 16, 2022
Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats.
Journal: Biochemical and biophysical research communications
Published: August 29, 2022
Correlation of Obesity and Overweight with Cervical Vascular Function Among Healthy Populations.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: July 26, 2022
Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice.
Journal: Drug design, development and therapy
Published: July 23, 2022
Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice.
Journal: Frontiers in endocrinology
Published: July 15, 2022
An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism.
Journal: Drug design, development and therapy
Published: July 07, 2022
Last Updated: 09/26/2026